While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

The California Horse Racing Board's website reports that Quarter Horse trainer Monty Arrossa's trainees have returned four ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

GLP-1 receptor agonist labels in the U.S. (although not ... Study strengths include the large sample, restriction to new GLP-1 users and results that were robust in multiple sensitivity analyses.

This guide explains why career goals matter, provides practical examples, and offers strategies for achieving them effectively. Establishing career goals brings clarity and purpose to our professional ...

The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved ...

This includes a Phase II-ready oral glucagon-like peptide-1 receptor agonist (GLP-1RA) ecnoglutide, a potential first-in-class oral amylin agonist, and a long-acting subcutaneous amylin agonist. These ...

NASA’s troubled Mars Sample Return program is stuck at a crossroads—and is likely to remain in limbo until at least 2026—agency officials said at a press briefing on Tuesday. To bring this ...

The question now is: will they? And if the Trump administration moves forward with Mars Sample Return (MSR), what will it look like? Could it involve a human mission to Mars instead of a series of ...

Use of GLP-1 receptor agonists reduced the risk of kidney failure and individual MACE components compared with placebo among patients with or without diabetes. Glucagon-like peptide-1 receptor ...